<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04992559</url>
  </required_header>
  <id_info>
    <org_study_id>2021-KY-039</org_study_id>
    <nct_id>NCT04992559</nct_id>
  </id_info>
  <brief_title>A Study of Toripalimab as Consolidation Therapy After Postoperative Chemoradiotherapy in HNSCC</brief_title>
  <official_title>A Phase II, Open-Label, Single-arm Study of Toripalimab As Consolidation Therapy After Postoperative Radiotherapy or Chemoradiotherapy in Patients With Head and Neck Squamous Cell Carcinomas (HNSCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase II, open label, single-arm and exploratory clinical trial. The purpose&#xD;
      of this study is to observe the efficacy and safety of consolidation immunotherapy with&#xD;
      Toripalimab following postoperative radiotherapy or chemoradiotherapy for patients with&#xD;
      locally advanced head and neck squamous cell carcinomas (HNSCC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-year Disease-Free Survival Rate</measure>
    <time_frame>2 years</time_frame>
    <description>The 2-year DFS rate was defined as the rate of progression or death due to disease recurrence within 2 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2-year overall survival rate</measure>
    <time_frame>2 years</time_frame>
    <description>Number of patients with evidenced death / number of total patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Media Disease-free Survival (mDFS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The time at which disease progression or death due to disease progression occurred in 50% of patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival will be defined as the time from day 1 of study treatment until death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>90 days after the first dose of study treatment</time_frame>
    <description>Percentage of adverse events that are possibly, probably or definitely related to study treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">41</enrollment>
  <condition>Head and Neck Squamous Cell Carcinomas</condition>
  <arm_group>
    <arm_group_label>Toripalimab Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Toripalimab consolidation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Consolidation Toripalimab</intervention_name>
    <description>Toripalimab consolidation therapy after radiotherapy or chemoradiotherapy, 240mg IV, every 3 weeks, until progressive disease (PD), start new anti-cancer therapy, intolerable toxicity, withdraw informed consent or other conditions that require study treatment discontinuation. Toripalimab will be given at a maximum of 12 months.</description>
    <arm_group_label>Toripalimab Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Postoperative with adverse prognostic factors in patients with locally advanced head&#xD;
             and neck squamous cell carcinoma.&#xD;
&#xD;
          -  Have received postoperative adjuvant radiotherapy (chemo) therapy, and the end of the&#xD;
             treatment is not more than 2 months.&#xD;
&#xD;
          -  Greater than or equal to 18 and less than 70 years of age at time of study entry.&#xD;
&#xD;
          -  ECOG performance status of 0 or 1.&#xD;
&#xD;
          -  Measurable disease as per RECIST 1.1.&#xD;
&#xD;
          -  Screening labs must meet the following criteria and must be obtained within 14 days&#xD;
             prior to registration:&#xD;
&#xD;
               1. Adequate hepatic and renal function as demonstrated by&#xD;
&#xD;
                    1. Serum creatinine &lt; 1.5 X ULN or CrCl &gt; 40mL/min (if using the&#xD;
                       Cockcroft-Gault formula below):&#xD;
&#xD;
                         -  Males: Creatinine CL (mL/min) = (Weight (kg) x (140 - Age))/(72 x serum&#xD;
                            creatinine (mg/dL)）&#xD;
&#xD;
                         -  Females: Creatinine CL (mL/min) = (Weight (kg) x (140 - Age))/(72 x&#xD;
                            serum creatinine (mg/dL))x 0.85&#xD;
&#xD;
                    2. AST/ALT ≤ 3 x ULN&#xD;
&#xD;
                    3. Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can&#xD;
                       have total bilirubin &lt; 3.0 mg/dL)&#xD;
&#xD;
               2. Adequate bone marrow function as demonstrated by:&#xD;
&#xD;
                    1. Absolute Neutrophil Count &gt;1,500/µL&#xD;
&#xD;
                    2. Platelets &gt; 100 X 103/µL&#xD;
&#xD;
                    3. Hemoglobin &gt; 9.0 g/dL&#xD;
&#xD;
          -  Women of reproductive potential should have a negative serum or urine pregnancy test&#xD;
             (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin&#xD;
             [HCG]) within 7 days of study enrollment.&#xD;
&#xD;
          -  Women of reproductive potential must use highly effective contraception methods to&#xD;
             avoid pregnancy for 3 months after the last dose of study drugs; &quot;women of&#xD;
             reproductive potential&quot; is defined as any female who has experienced menarche and who&#xD;
             has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or&#xD;
             who is not postmenopausal; menopause is defined clinically as 12 months of amenorrhea&#xD;
             in a woman over 45 in the absence of other biological or physiological causes; in&#xD;
             addition, women under the age of 55 must have a documented serum follicle stimulating&#xD;
             hormone (FSH) level less than 40 mIU/mL.&#xD;
&#xD;
          -  Men of reproductive potential who are sexually active with women of reproductive&#xD;
             potential must use any contraceptive method with a failure rate of less than 1% per&#xD;
             year; men who are receiving the study medications will be instructed to adhere to&#xD;
             contraception for 3 months after the last dose of study drugs; men who are azoospermic&#xD;
             do not require contraception.&#xD;
&#xD;
          -  Ability to understand and willingness to sign an IRB approved written informed consent&#xD;
             document (or that of legally authorized representative, if applicable).&#xD;
&#xD;
          -  Subject is willing and able to comply with the protocol for the duration of the study&#xD;
             including undergoing treatment and scheduled visits and examinations including follow&#xD;
             up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Is currently participating in or has participated in a study of an investigational&#xD;
             agent within 4 weeks of the first dose of treatment or has not recovered (i.e., ≤&#xD;
             Grade 1 or at baseline) from adverse events due to agents administered more than 4&#xD;
             weeks earlier.&#xD;
&#xD;
          -  Has had another known invasive malignancy within the previous 5 years （With the&#xD;
             exception of basal cell carcinoma of the skin, carcinoma in situ of the cervix, and&#xD;
             papillary carcinoma of the thyroid, which has been cured）.&#xD;
&#xD;
          -  If subject received major surgery for any other reason, they must have recovered&#xD;
             adequately from the toxicity and/or complications from the intervention prior to&#xD;
             starting therapy.&#xD;
&#xD;
          -  Active, known or suspected autoimmune disease.&#xD;
&#xD;
          -  Has evidence of interstitial lung disease or active, non-infectious pneumonitis.&#xD;
&#xD;
          -  Has an active infection requiring systemic therapy.&#xD;
&#xD;
          -  Has received prior therapy with an anti-PD-1 antibody .&#xD;
&#xD;
          -  A history of allergic reaction attributed to compounds of similar chemical or biologic&#xD;
             composition to the treatment or other agents used in the study.&#xD;
&#xD;
          -  Has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial.&#xD;
&#xD;
          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the trial, starting with the pre-screening or screening visit&#xD;
             through 23 weeks after the last dose of trial treatment.&#xD;
&#xD;
          -  Has a known history of Human Immunodeficiency Virus (HIV) infection (HIV 1/2&#xD;
             antibodies).&#xD;
&#xD;
          -  Has known active Hepatitis B or C.&#xD;
&#xD;
          -  Known history of active TB ( bacillus tuberculosis ).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Song Fan, Doctor degrees</last_name>
    <phone>13570536658</phone>
    <email>fansong2@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Song Fan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Song Fan, Doctor degree</last_name>
      <phone>020-81332471</phone>
      <email>fansong2@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Song Fan, Doctor degree</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qiong Yang, Doctor degree</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 28, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>October 2, 2021</last_update_submitted>
  <last_update_submitted_qc>October 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Song Fan, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

